The early stages of clinical development are critical, decisions made here can determine the efficiency, cost, and ultimate success of an entire program. With the evolving landscape of early phase drug development, sponsors need flexible yet robust statistical approaches to ensure that promising compounds are evaluated effectively and efficiently. Getting this stage right not only accelerates timelines but also maximizes the chances of bringing safe, effective treatments to patients.
This webinar shares practical insights into trial design, highlights important statistical considerations, and explores recent developments shaping early phase research.
Speakers:
- Sam Hinsley, Statistics Manager
- Lisa Gibbons (Moderator), Senior Statistician
Learning Points:
- Gain clarity on what biotech and pharma developers should prioritize when planning early phase studies.
- Understand key statistical considerations that directly influence trial design, decision-making, and downstream success.
- Hear the latest updates on innovative approaches in early phase clinical trials that could strengthen your development pipeline
